Rabies vaccine - GlaxoSmithKline

Drug Profile

Rabies vaccine - GlaxoSmithKline

Alternative Names: KD-357; Purified chicken-embryo cell rabies vaccine; RabAvert; Rabipur; Rabivac; Rasilvax

Latest Information Update: 22 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer GlaxoSmithKline; Kaketsuken; Sanofi
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Rabies

Most Recent Events

  • 09 Dec 2016 GlaxoSmithKline plans an extension phase IV trial for Rabies in China (IM) (NCT02991872)
  • 01 Aug 2015 Novartis completes a phase III trial for Rabies in Philippines & Thailand (NCT02177032)
  • 02 Jul 2015 Novartis initiates a phase III trial for Rabies in Austria (EudraCT2015-000382-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top